SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is surging after positive topline results from a maintenance study of its obesity drug VK2735, which showed up to 97% of prior weight loss maintained on every-other-week dosing, roughly 22% placebo-adjusted weight loss through 33 weeks with no plateau, and tolerability similar to placebo. Bulls call the data best-in-class versus Lilly and Novo and speculate about a buyout, partnership, or short squeeze given elevated short interest, while bears view the muted reaction as sell-the-news, citing dilution risk from a shelf offering and unresolved questions such as lean mass preservation.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi shares popped premarket after the company announced it has gone live with stablecoin settlement via SoFiUSD across Mastercard's network, migrating its $25B card program to blockchain settlement. Community reaction quickly turned to frustration as gains faded, with traders debating whether the sell-off reflects market manipulation and short pressure or a recurring 

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk's removal from the S&P 500 and move to the S&P SmallCap 600 dominates the conversation, with traders debating whether the unusually heavy trading volume around the rebalance reflects forced index-fund selling, short covering, or institutional accumulation. Alongside the index exit, the community is largely angry at management  especially CEO Jeff Green's newly repriced option package, executive stock grants, and a 15% workforce reduction  while bulls argue the beaten-down stock, heavy short interest, and cash-rich balance sheet could set up a rebound after the index-driven selling ends.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending following the announcement of a 100 million dollar design win for its Alloy Kore software, which investors believe validates the company's QNX automotive platform and strengthens its growth outlook ahead of the upcoming earnings release. While some traders express frustration over price volatility and alleged manipulation, the community remains largely bullish, focusing on the expanded revenue backlog and expectations for positive forward guidance.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

XNDU is trending on a steep selloff from the $40 range to around $10, with traders split between calling the drop an overreaction worth buying and labeling it one of the easiest shorts on the market, with bearish posters citing claimed short interest near 68% of the float and a standard 180-day lockup expiration as reasons the stock stays under pressure. The debate also weighs Xanadu's photonic quantum approach  bulls call it the future while skeptics say it needs roughly a decade more development  alongside disappointment that announcements such as a Lockheed Martin partnership and a Mitsubishi Chemical collaboration carried no revenue figures, plus uncertainty over a potential 300M+ Canadian government grant.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is surging through the long-capped $1.50 resistance level, a move traders widely attribute to a broad crypto short squeeze that forced large-scale liquidations of heavily shorted altcoin positions. Bulls are calling it the start of a new bull run and a potential decoupling from Bitcoin, while skeptics argue it is a news-less, squeeze-driven pump that will likely retrace given XRP's continued correlation with Bitcoin.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Traders are focused on federal cannabis rescheduling momentum, reacting to a federal appeals court's denial of opponents' request to block the Schedule III process while awaiting ALJ Judge Julius's recommendation, which many in the community speculate could arrive at any moment. Discussion is split between bulls treating the pending recommendation as the sector's long-awaited catalyst and skeptics calling it a potential "nothing burger" given that HHS, the DEA, and the President have already signaled support for Schedule III, with frustration over repeated rejections at a key resistance level fueling manipulation complaints.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin shares are sliding alongside a broader selloff in defense stocks, a move many traders find counterintuitive given the ongoing Iran conflict, reports of depleted US missile stockpiles, a record backlog, and a string of new contract and production-expansion awards. The community is split, with dip-buyers calling the drop unwarranted and pointing to munitions-replenishment demand, while others cite sector rotation, profit-taking, and potential defense-budget or political headwinds.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is breaking out to new 52-week highs after Cantor Fitzgerald upgraded the stock to Overweight, citing a stronger-than-expected YARTEMLEA launch, while traders also point to Novo Nordisk adding zaltenibart  including an IgA nephropathy program  to its development roadmap ahead of its capital markets day. The community is largely celebratory, with short-squeeze talk and expectations of follow-on analyst coverage, though some question whether an upgrade alone justifies the size of the move.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as founder Patrick Soon-Shiong teased a blockchain-based tokenized stock trading push at Nant following the SEC's Innovation Exemption, prompting speculation among traders that IBRX shares could eventually be tokenized and pressure heavily shorted positions. The community is split between bulls framing tokenization as a potential squeeze catalyst and skeptics calling it hype with no announced company action, while others focus on rumors of a possible Turkish approval for Anktiva and Soon-Shiong's meetings around the UN gathering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Blueprint Medicines Stock  Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith

Equity

Analysts revised price targets near the deal’s $129-per-share valuation.

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines 

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.


Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Blueprint Medicines Corp

Neutral Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BPMC Blueprint Medicines Corp

Latest BPMC News